Rathbones Group PLC Boosts Stock Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Key Points

• Rathbones Group PLC has increased its holdings in Thermo Fisher Scientific Inc. by 5.7%, now owning 841,990 shares, which constitutes approximately 2.0% of its portfolio.
• Institutional investors hold a significant majority of 89.23% of Thermo Fisher's shares, indicating strong backing from these financial entities.
• Thermo Fisher Scientific reported an EPS of $5.36 for the latest quarter, surpassing analysts' expectations and showing a year-over-year revenue increase of 2.9%.

Rathbones Group PLC boosted its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 5.7% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 841,990 shares of the medical research company's stock after buying an additional 45,673 shares during the quarter. Thermo Fisher Scientific accounts for about 2.0% of Rathbones Group PLC's portfolio, making the stock its 9th largest holding. Rathbones Group PLC owned about 0.22% of Thermo Fisher Scientific worth $418,974,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the business. Brighton Jones LLC grew its stake in Thermo Fisher Scientific by 28.9% in the 4th quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company's stock valued at $2,293,000 after acquiring an additional 988 shares during the period. Revolve Wealth Partners LLC increased its stake in Thermo Fisher Scientific by 4.2% during the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock worth $255,000 after acquiring an additional 20 shares during the last quarter. Bank Pictet & Cie Europe AG increased its stake in Thermo Fisher Scientific by 0.3% during the fourth quarter. Bank Pictet & Cie Europe AG now owns 153,157 shares of the medical research company's stock worth $79,677,000 after acquiring an additional 461 shares during the last quarter. Sagespring Wealth Partners LLC purchased a new position in Thermo Fisher Scientific during the 4th quarter valued at about $1,242,000. Finally, Bragg Financial Advisors Inc grew its stake in shares of Thermo Fisher Scientific by 1.1% in the fourth quarter. Bragg Financial Advisors Inc now owns 12,960 shares of the medical research company's stock worth $6,742,000 after acquiring an additional 143 shares in the last quarter. 89.23% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on TMO. Stifel Nicolaus decreased their target price on Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating for the company in a report on Thursday, April 24th. Royal Bank Of Canada decreased their price target on Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating for the company in a report on Thursday, April 24th. The Goldman Sachs Group set a $610.00 price target on Thermo Fisher Scientific and gave the company a "buy" rating in a research note on Wednesday, April 23rd. Wall Street Zen downgraded Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a research note on Sunday. Finally, Wells Fargo & Company dropped their price target on Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating for the company in a research report on Thursday, July 24th. Seven research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. According to data from MarketBeat, Thermo Fisher Scientific has a consensus rating of "Moderate Buy" and a consensus target price of $593.00.

Insider Activity

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the company's stock in a transaction dated Wednesday, August 6th. The shares were sold at an average price of $451.82, for a total value of $4,518,200.00. Following the completion of the transaction, the chief executive officer owned 115,174 shares in the company, valued at approximately $52,037,916.68. This represents a 7.99% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Gianluca Pettiti sold 400 shares of the company's stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $479.98, for a total transaction of $191,992.00. Following the completion of the transaction, the executive vice president owned 22,367 shares of the company's stock, valued at approximately $10,735,712.66. This trade represents a 1.76% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 18,400 shares of company stock valued at $8,345,792. 0.33% of the stock is owned by insiders.

Thermo Fisher Scientific Stock Up 0.2%

Thermo Fisher Scientific stock traded up $0.83 during trading on Thursday, reaching $485.62. 1,955,228 shares of the company's stock were exchanged, compared to its average volume of 2,498,410. Thermo Fisher Scientific Inc. has a 52-week low of $385.46 and a 52-week high of $627.88. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. The firm has a market cap of $183.38 billion, a price-to-earnings ratio of 28.09, a PEG ratio of 2.55 and a beta of 0.74. The company's 50-day moving average is $431.32 and its two-hundred day moving average is $462.11.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.22 by $0.14. The business had revenue of $10.86 billion for the quarter, compared to analyst estimates of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The company's revenue for the quarter was up 2.9% on a year-over-year basis. During the same quarter in the prior year, the business posted $5.37 EPS. On average, analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be given a $0.43 dividend. The ex-dividend date is Monday, September 15th. This represents a $1.72 annualized dividend and a yield of 0.4%. Thermo Fisher Scientific's dividend payout ratio is 9.95%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.